Results 61 to 70 of about 8,557 (171)

Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study

GastroHep, 2023
Background and Aims. Regulatory pathways compare biosimilars with originator molecules only and not with other biosimilars. With the development of multiple infliximab biosimilars, patients may be asked to transition between them.
Clare Harris, Richard James Harris, David Young, Martin McDonnell, Bridget Clancy, Justin Harvey, Carlos Araujo, Ines Iria, Joao Goncalves, Susan Latter, J. R. Fraser Cummings   +10 more
doaj   +1 more source

Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland [PDF]

, 2017
Increasing numbers of biosimilar medicines are becoming available. The objective of this survey was to assess awareness of and attitudes to biosimilars amongst physicians (medical specialists and General Practitioners (GPs)) and community pharmacists in ...
Bermingham, Margaret, Griffin, Brendan T., Hallinan, Frank, Leonard, Maurice, Moore, Una, Morris, J. Michael, O'Callaghan, Joan   +6 more
core   +1 more source

Evaluation of novel cardiovascular risk calculators in patients with rheumatoid arthritis

Journal of Rheumatic Diseases
Objective: CT-P13, a biosimilar of infliximab, is widely used for treating ankylosing spondylitis (AS). However, the formation of anti-drug antibodies (ADAs) can reduce its efficacy.
Dionicio Angel Galarza-Delgado, Valeria Gonzalez-Gonzalez, Natalia Guajardo-Jauregui, Jesus Alberto Cardenas-de la Garza, Rosa Icela Arvizu-Rivera, Maria Fernanda Elizondo-Benitez, Andrea Lizbeth Guajardo-Aldaco, Jose Ramon Azpiri-Lopez, Iris Jazmin Colunga-Pedraza   +8 more
doaj   +1 more source

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results [PDF]

, 2017
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy,
Argüelles Arias, Federico, Castro Laria, Luisa, Guerra Veloz, María Fernanda, Maldonado Pérez, Belén, Merino Bohórquez, Vicente, Perea Amarillo, Raúl, Romero Gómez, Manuel, Vilches Arenas, Ángel   +7 more
core  

Differentiating the Clinical and Variant Spectrum of Hardikar Syndrome From Other MED12‐Related Developmental Disorders

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT The rare X‐linked female‐restricted Hardikar syndrome (HDKR, OMIM # 301068) is characterized by multiple congenital anomalies including orofacial clefts, gastrointestinal, genitourinary, and cardiac anomalies, but cognitive and neurobehavioral development is rarely impaired.
Tinne Warmoeskerken, Miel Theunis, Kris Van den Bogaert, Koenraad Devriendt, Jeroen Breckpot   +4 more
wiley   +1 more source

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. [PDF]

, 2016
BACKGROUND: Ulcerative colitis (UC) is the most common form of inflammatory bowel disease in the UK. UC can have a considerable impact on patients' quality of life. The burden for the NHS is substantial. OBJECTIVES: To evaluate the clinical effectiveness
Archer, R., Basarir, H., Cantrell, A., Carroll, C., Harvey, R., Hoque, S., Lobo, A., Martyn-St James, M., Ren, S., Stevens, J., Tappenden, P.   +10 more
core   +2 more sources

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis [PDF]

Journal of Crohn's and Colitis, 2016
CT-P13 is the first biosimilar to infliximab that has been approved for the same indications as its originator infliximab. No data are available on the effect of infliximab biosimilar on mucosal healing. The aim of this study was to evaluate the efficacy of CT-P13 induction therapy on mucosal healing in patients with ulcerative colitis [UC].UC patients,
Farkas, Klaudia, Rutka, Mariann, Golovics, Petra A., Végh, Zsuzsanna, Lovász, Barbara D., Nyári, Tibor, Gecse, Krisztina B., Kolar, Martin, Bortlik, Martin, Duricova, Dana, Machkova, Nadezda, Hruba, Veronika, Lukas, Martin, Mitrova, Katarina, Malickova, Karin, Bálint, Anita, Nagy, Ferenc, Bor, Renáta, Milassin, Ágnes, Szepes, Zoltán, Palatka, Károly, Lakatos, Péter L., Lukas, Milan, Molnár, Tamás   +23 more
openaire   +4 more sources

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

Therapeutic Advances in Gastroenterology, 2019
Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from follow-up periods longer than 1 year are still scarce.
María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdes Delgado, Luisa Castro Laria, Belén Maldonado Pérez, Raúl Perea Amarillo, Vicente Merino Bohórquez, Ángel Caunedo Álvarez, Ángel Vilches Arenas, Federico Argüelles-Arias   +9 more
doaj   +1 more source

Nicotine pouches and clinical outcomes related to smoking cessation: A systematic review of randomized trials

Addiction, EarlyView.
Abstract Background and aims Tobacco‐free nicotine pouches (NPs) are oral nicotine products promoted by manufacturers and some researchers as tools that may reduce nicotine cravings and support smoking reduction or cessation. However, evidence regarding their actual clinical impact remains limited.
Javad Heshmati, Spencer Shahen, Emma Lynn Bates, Sarah Visintini, Evyanne Quirouette, Kerri‐Anne Mullen, Hassan Mir   +6 more
wiley   +1 more source

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.

PLoS ONE, 2018
IntroductionTNF-α-neutralizing antibodies, such as infliximab (IFX) and adalimumab (ADA), are effective in the treatment of inflammatory bowel diseases (IBD), but they are expensive and become ineffective when patients develop anti-IFX or anti-ADA ...
D J Buurman, T Blokzijl, E A M Festen, B T Pham, K N Faber, E Brouwer, G Dijkstra   +6 more
doaj   +1 more source